Capstone Therapeutics Closes $10 Million Financing Facility to Boost Southeast U.S. Acquisition Strategy

Reuters
Jul 30
Capstone <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Closes $10 Million Financing Facility to Boost Southeast U.S. Acquisition <a href="https://laohu8.com/S/MSTR">Strategy</a>

Capstone Holding Corp. (NASDAQ:CAPS) has announced the closing of a $10 million convertible note facility, with an initial $3 million draw to support its M&A strategy. The financing will back Capstone's expansion into a high-growth Southeastern U.S. market, facilitated by a deal under a letter of intent. This transaction marks a significant step for Capstone as it targets a full-year revenue run-rate of $100 million through a combination of organic growth and strategic acquisitions. The facility, which has an 8.34% original issue discount and a 7.0% annual interest rate, will mature on July 29, 2026, and is convertible into Capstone shares at $1.72 per share. Joseph Gunnar & Co., LLC served as the exclusive placement agent for this offering.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1054693) on July 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10